Attorney Docket No.: JHUC-008-101

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Michela Gallagher

Application No. : 10/722,357 Confirmation No. 4705

Filed: November 24, 2003

For : TARGET FOR THERAPY OF COGNITIVE

**IMPAIRMENT** 

Group Art Unit : 1611

Examiner : Kyle A. Purdy

New York, New York 10036

February 8, 2010

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants hereby make of record the following documents in the above-identified patent application:\*

## **Non-Patent Literature Documents**

Bittigau et al., "Antiepileptic drugs and apoptotic neurodegeneration in the developing brain," PNAS, 99:15089-15094 (2002).

Meador et al., "Comparative cognitive effects of phenobarbital, phenytoin, and valproate in healthy adults," Neurology, 45:1494-1499 (1995).

<sup>\*</sup>A completed Form PTO/SB/08A/B listing these documents is attached hereto.

## **REMARKS**

The documents contained in this Supplemental Information Disclosure Statement were cited in a November 9, 2009 Office Action in counterpart Japanese Patent Application 2004-55830.

Copies of the aforementioned documents, which are listed on the accompanying Form PTO/SB/08A/B, are enclosed herewith.

Applicants respectfully request that the above documents be (1) fully considered by the Examiner during the course of the examination of this application and (2) printed on any patent issuing from this application. Applicants also request that a copy of the enclosed Form PTO/SB/08A/B, as considered and duly initialed by the Examiner, be forwarded to the undersigned with the next communication.

This Statement is being submitted before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. In accordance with 37 C.F.R. § 1.97(b)(4), applicants believe that submission of this Statement requires no fee. If, however, any additional fee is due, the Director is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. <u>06-1075</u>, Order No. <u>JHUC-008-101</u>.

Respectfully submitted,

/JAMES F. HALEY, JR./

James F. Haley, Jr. (Reg. No. 27,794) Attorney for Applicants

ROPES & GRAY LLP Customer No. 1473 1211 Avenue of the Americas New York, New York 10036 Tel.: (212) 596-9000

Fax: (212) 596-9090